The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide

European Journal of Pharmacology

Volumn 746, Issue , 2015, Pages 167-173

  Töllner, Kathrin ^a,b   Brandt, Claudia ^a,b   Römermann, Kerstin ^a,b   Löscher, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Blood brain barrier; Cation chloride cotransporters; Drug transport; Epilepsy; Neonatal seizures

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; BUMETANIDE; MULTIDRUG RESISTANCE PROTEIN; PROBENECID; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTICONVULSIVE AGENT; DIURETIC AGENT; LOOP DIURETIC AGENT; NERVE PROTEIN; ORGANIC ANION TRANSPORTER; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIURETIC ACTIVITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG BRAIN PLASMA RATIO; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TRANSPORT; FEMALE; IN VITRO STUDY; LLC PK1 CELL LINE; MDCK CELL LINE; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; TIME SERIES ANALYSIS; URINARY EXCRETION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD BRAIN BARRIER; BRAIN; CELL LINE; CHEMISTRY; DOG; DRUG EFFECTS; DRUG INTERACTION; GENETICS; HALF LIFE TIME; HUMAN; KIDNEY; METABOLISM; NERVE CELL; OUTBRED STRAIN; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTICONVULSANTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BUMETANIDE; CELL LINE; DIURETICS; DOGS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; KIDNEY; MEMBRANE TRANSPORT MODULATORS; MICE; NERVE TISSUE PROTEINS; NEURONS; ORGANIC ANION TRANSPORTERS; PROBENECID; RECOMBINANT PROTEINS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84914126995     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.11.019     Document Type: Article

References (41)

1. N.J. Abbott, A.A. Patabendige, D.E. Dolman, S.R. Yusof, and D.J. Begley Structure and function of the blood-brain barrier Neurobiol. Dis. 37 2010 13 25
2. S. Baltes, M. Fedrowitz, C. Luna-Tortós, H. Potschka, and W. Löscher Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays J. Pharmacol. Exp. Ther. 320 2007 331 343
3. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance- associated proteins J. Natl. Cancer Inst. 92 2000 1295 1302
4. P. Borst, C. de Wolf, and W.K. van de Multidrug resistance-associated proteins 3, 4, and 5 Pflugers Arch. 453 2007 661 673
5. C. Brandt, M. Nozadze, N. Heuchert, M. Rattka, and W. Löscher Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy J. Neurosci. 30 2010 8602 8612
6. T. Brismar, A. Gruber, and C. Peterson Increased cation transport in mdr1-gene-expressing K562 cells Cancer Chemother. Pharmacol. 36 1995 87 90
7. G. Burckhardt Drug transport by Organic Anion Transporters (OATs) Pharmacol. Ther. 136 2012 106 130
8. Goda, S., Thorsheim, H. R., Taskar, K. S., Thomas, A. J., and Smith, Q. R. Restricted brain distribution of bumetanide is mediated by active efflux transporters (rat Oatp & OAT3) at the blood-brain barrier. American Association of Pharmaceutical Scientists AAPS 2010.Published Meeting Abstracts. Number SA7187 Ref Type: Abstract; 2010.
9. M. Hasegawa, H. Kusuhara, M. Adachi, J.D. Schuetz, K. Takeuchi, and Y. Sugiyama Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide J. Am. Soc. Nephrol. 18 2007 37 45
10. M.M. Hoffman, and P.D. Roepe Analysis of ion transport perturbations caused by hu MDR 1 protein overexpression Biochemistry 36 1997 11153 11168
11. J.A. Horz, W. Honscha, and E. Petzinger Bumetanide is not transported by the Ntcp or by the oatp: evidence for a third organic anion transporter in rat liver cells Biochim. Biophys. Acta 1300 1996 114 118
12. K.T. Kahle, K.J. Staley, B.V. Nahed, G. Gamba, S.C. Hebert, R.P. Lifton, and D.B. Mount Roles of the cation-chloride cotransporters in neurological disease Nat. Clin. Pract. Neurol. 4 2008 490 503
13. K. Kaila, T.J. Price, J.A. Payne, M. Puskarjov, and J. Voipio Cation-chloride cotransporters in neuronal development, plasticity and disease Nat. Rev. Neurosci. 15 2014 637 654
14. Y. Kobayashi, M. Ohbayashi, N. Kohyama, and T. Yamamoto Mouse organic anion transporter 2 and 3 (mOAT2/3[Slc22a7/8]) mediates the renal transport of bumetanide Eur. J. Pharmacol. 524 2005 44 48
15. H. Kusuhara, and Y. Sugiyama Active efflux across the blood-brain barrier: role of the solute carrier family NeuroRx 2 2005 73 85
16. H.S. Lau, L.J. Shih, and D.E. Smith Effect of probenecid on the dose-response relationship of bumetanide at steady state J. Pharmacol. Exp. Ther. 227 1983 51 54
17. M. Leggas, M. Adachi, G.L. Scheffer, D. Sun, P. Wielinga, G. Du, K.E. Mercer, Y. Zhuang, J.C. Panetta, B. Johnston, R.J. Scheper, C.F. Stewart, and J.D. Schuetz Mrp4 confers resistance to topotecan and protects the brain from chemotherapy Mol. Cell Biol. 24 2004 7612 7621
18. W. Löscher, and H. Potschka Drug resistance in brain diseases and the role of drug efflux transporters Nat. Rev. Neurosci. 6 2005 591 602
19. W. Löscher, H. Klitgaard, R.E. Twyman, and D. Schmidt New avenues for antiepileptic drug discovery and development Nat. Rev. Drug Discov. 12 2013 757 776
20. W. Löscher, M. Puskarjov, and K. Kaila Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments Neuropharmacology 69 2013 62 74
21. C. Luna-Tortós, M. Fedrowitz, and W. Löscher Several major antiepileptic drugs are substrates for human P-glycoprotein Neuropharmacology 55 2008 1364 1375
22. R. Miles, P. Blaesse, G. Huberfeld, L. Wittner, and K. Kaila Chloride homeostasis and GABA signaling in temporal lobe epilepsy J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta, Jaspers Basic Mechanisms Of The Epilepsies Fourth edition 2012 Oxford University Press New York 581 590
23. M.E. Morris, and M.A. Felmlee Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid AAPS J. 10 2008 311 321
24. Y. Murakami, N. Kohyama, Y. Kobayashi, M. Ohbayashi, H. Ohtani, Y. Sawada, and T. Yamamoto Functional characterization of human monocarboxylate transporter 6 (SLC16A5) Drug Metab. Dispos. 33 2005 1845 1851
25. U.B. Olsen The pharmacology of bumetanide Acta Pharmacol. Toxicol. (Copenh) 41 1977 1 29
26. E. Petzinger, M. Blumrich, B. Bruhl, U. Eckhardt, W. Follmann, W. Honscha, J.A. Horz, N. Muller, L. Nickau, M. Ottallah-Kolac, H.D. Platte, A. Schenk, K. Schuh, K. Schulz, and S. Schulz What we have learned about bumetanide and the concept of multispecific bile acid/drug transporters from the liver J. Hepatol. 24 Suppl. 1 1996 S42 S46
27. H. Potschka, M. Fedrowitz, and W. Löscher Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity J. Pharmacol. Exp. Ther. 306 2003 124 131
28. Pressler, R., 2014. Bumetanide. Proceedings of the Twelth EILAT Conference on New Antiepileptic Drugs (EILAT XII), August 31-September 3, 2014, Madrid, Spain.
29. R.M. Pressler, and B. Mangum Newly emerging therapies for neonatal seizures Semin. Fetal Neonatal Med. 18 2013 216 223
30. M. Puskarjov, K.T. Kahle, E. Ruusuvuori, and K. Kaila Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures Epilepsia 55 2014 806 818
31. G. Reid, P. Wielinga, N. Zelcer, M. de Haas, L. van Deemter, J. Wijnholds, J. Balzarini, and P. Borst Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5 Mol. Pharmacol. 63 2003 1094 1103
32. C.A. Ritter, G. Jedlitschky, S.H. Meyer zu, M. Grube, K. Kock, and H.K. Kroemer Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5) Drug Metab. Rev. 37 2005 253 278
33. M. Roth, A. Obaidat, and B. Hagenbuch OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies Br. J. Pharmacol. 165 2012 1260 1287
34. Y. Shitara, H. Sato, and Y. Sugiyama Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs Annu. Rev. Pharmacol. Toxicol. 45 2005 689 723
35. M. Simonato, A.R. Brooks-Kayal, J. Engel Jr., A.S. Galanopoulou, F.E. Jensen, S.L. Moshe, T.J. OBrien, A. Pitkanen, K.S. Wilcox, and J.A. French The challenge and promise of anti-epileptic therapy development in animal models Lancet Neurol. 13 2014 949 960
36. D.E. Smith, and H.S. Lau Determinants of bumetanide response in the dog: effect of probenecid J. Pharmacokinet. Biopharm. 11 1983 31 46
37. K. Töllner, C. Brandt, M. Töpfer, G. Brunhofer, T. Erker, M. Gabriel, P.W. Feit, J. Lindfors, K. Kaila, and W. Löscher A novel prodrug-based strategy to increase effects of bumetanide in epilepsy Ann. Neurol. 75 2014 550 562
38. M. Töpfer, K. Töllner, C. Brandt, F. Twele, S. Bröer, and W. Löscher Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy Eur. J. Neurosci. 39 2014 673 687
39. Y. Uchida, J. Kamiie, S. Ohtsuki, and T. Terasaki Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter Pharm. Res. 24 2007 2281 2296
40. Y. Uchida, S. Ohtsuki, Y. Katsukura, C. Ikeda, T. Suzuki, J. Kamiie, and T. Terasaki Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J. Neurochem. 117 2011 333 345
41. A.L. VanWert, M.R. Gionfriddo, and D.H. Sweet Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology Biopharm. Drug Dispos. 31 2010 1 71